Is Verrica Pharmaceuticals Inc (VRCA) Stock About to Get Hot Tuesday?

Overall market sentiment has been high on Verrica Pharmaceuticals Inc (VRCA) stock lately. VRCA receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Verrica Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VRCA!

See Full VRCA Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With VRCA Stock Today?

Verrica Pharmaceuticals Inc (VRCA) stock has fallen -1.78% while the S&P 500 is higher by 0.24% as of 9:39 AM on Tuesday, Mar 26. VRCA has fallen -$0.09 from the previous closing price of $5.06 on volume of 172,662 shares. Over the past year the S&P 500 is higher by 31.50% while VRCA has fallen -22.95%. VRCA lost -$1.48 per share in the over the last 12 months.

More About Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts. Click Here to get the full Stock Report for Verrica Pharmaceuticals Inc stock.